Tonix Pharmaceuticals Holding. has filed a patent for a method to treat fibromyalgia and its associated symptoms using transmucosal administration of 5.6 mg cyclobenzaprine HCl per day in specific eutectic forms. The method includes a basifying agent in the dosage units. GlobalData’s report on Tonix Pharmaceuticals Holding gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Tonix Pharmaceuticals Holding, Cancer treatment biomarkers was a key innovation area identified from patents. Tonix Pharmaceuticals Holding's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment method for fibromyalgia using cyclobenzaprine hcl eutectic

Source: United States Patent and Trademark Office (USPTO). Credit: Tonix Pharmaceuticals Holding Corp

A patent application (Publication Number: US20240024256A1) describes a method for treating fibromyalgia and its associated symptoms of pain, sleep disturbance, and fatigue. The method involves administering 5.6 mg of cyclobenzaprine HCl per day in one or more dosage units through transmucosal administration. The cyclobenzaprine HCl is in the form of various eutectics, including a mixture of cyclobenzaprine and mannitol or d-mannitol, and granules with specific compositions. The dosage units also contain a basifying agent to enhance the treatment effectiveness.

Furthermore, the patent application details a multiple-variable dose method for treating fibromyalgia, involving the administration of different dosage units over specific periods. The method includes the daily administration of specific dosage units containing cyclobenzaprine HCl for a set duration, followed by a second dosage unit with a higher concentration for as long as needed. The transmucosal administration can be through sublingual, buccal, intranasal, or palatal routes, and the basifying agent used includes various compounds like phosphates, carbonates, and acetates. The treatment aims to reduce pain, improve sleep quality, reduce sleep disturbances, and alleviate fatigue, with pain reduction being a key measure of treatment effectiveness, showing a reduction of over 30% in some cases. The method is intended for human subjects suffering from fibromyalgia and its associated symptoms.

To know more about GlobalData’s detailed insights on Tonix Pharmaceuticals Holding, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies